Stocks · News reference
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
LB Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2026
LB Pharmaceuticals announced its financial results for the third quarter of 2026, reporting a net loss of $59.1 million and a cash position of $403.8 million.
Avalyn Pharma Announces Participation in Upcoming Investor Conferences
Avalyn Pharma Inc. announced its scheduled participation in three upcoming investor conferences in November and December 2026.
SailPoint Executive Comments on Autonomous Agent Security in UK Budget Context
Matt Bruun, VP EMEA Agentic Technology Specialist at SailPoint, highlighted the security risks posed by the rapid adoption of autonomous agents in UK enterprises.
Bank of America Maintains Neutral Rating on SailPoint
Analyst Tal Liani of Bank of America Securities has reaffirmed a 'Neutral' rating on SailPoint (SAIL) with a price target of $24.
BB Biotech Adds LB Pharmaceuticals to Investment Portfolio
BB Biotech has initiated a new investment position in clinical-stage biopharmaceutical company LB Pharmaceuticals as part of its portfolio strategy.